How PD-1 therapy affects immune cells in advanced cancers
Part of Cancer, Lungs & breathing, Skin clinical trials.
This study looks at how your immune system responds to PD-1/PD-L1 immunotherapy (drugs like Keytruda or Opdivo) for advanced melanoma, lung cancer, and similar cancers. It involves regular blood tests to track your immune cells, which may help doctors understand why these treatments work for some people better than others.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a confirmed advanced (spread beyond the original site) or stage IV cancer (like melanoma or lung cancer)
- Your doctor recommends starting a PD-1/PD-L1 immunotherapy drug (like Keytruda or Opdivo), even if you have had this type of treatment before
- You are willing to give blood samples at multiple visits for research
- You are not pregnant or nursing, and if you could become pregnant, you agree to use effective birth control
- You are able to understand and sign the consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at tissue and scan-related markers (“biomarkers”) to better understand how immunotherapy works in people with advanced melanoma. You may receive standard first-line immunotherapy, and your recent scans and health details will help researchers study why some people respond better than others.
This trial is studying how PD-1 antibody therapy (a type of immunotherapy that helps your immune system fight cancer) affects the immune system in people with various cancers. It may be a good fit if you have a confirmed cancer diagnosis and have your medical records and immune test results available.
This study looks at immune cells in your blood to find patterns that might show how well a treatment called anti-PD1 immunotherapy works for melanoma. Your participation could help doctors better understand who benefits from this therapy.
This trial tests whether injecting immune-boosting drugs directly into melanoma tumors, alongside the immunotherapy pembrolizumab, can help people whose cancer has not responded to previous immunotherapy. It aims to shrink tumors and improve treatment outcomes.
This study looks at a simple blood test to see if it can predict how well your cancer will respond to immunotherapy. You will give blood samples before and during treatment, and the researchers will analyze small particles in your blood to find clues about your likely response.
This study looks at how your immune system works in non-small cell lung cancer and whether it predicts how well you'll respond to a type of immunotherapy called anti-PD-1/PD-L1 drugs. Researchers will study your tumor tissue to understand why some patients benefit more than others.
Hear when a new Clinical Stage III Cutaneous Melanoma AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.